Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan
Purpose To analyze retrospectively the results of intraoperative radiotherapy (IORT) with or without external beam radiotherapy (± EBRT) for localized pancreatic cancer in the past three decades and to analyze prognostic factors by multivariate analysis. Methods and Materials Records for 322 patient...
Gespeichert in:
Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2012-07, Vol.83 (4), p.e507-e511 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e511 |
---|---|
container_issue | 4 |
container_start_page | e507 |
container_title | International journal of radiation oncology, biology, physics |
container_volume | 83 |
creator | Jingu, Keiichi, M.D Tanabe, Takaya, M.D Nemoto, Kenji, M.D Ariga, Hisanori, M.D Umezawa, Rei, M.D Ogawa, Yoshihiro, M.D Takeda, Ken, M.D Koto, Masashi, M.D Sugawara, Toshiyuki, M.D Kubozono, Masaki, M.D Shimizu, Eiji, M.D Abe, Keiko, M.D Yamada, Shogo, M.D |
description | Purpose To analyze retrospectively the results of intraoperative radiotherapy (IORT) with or without external beam radiotherapy (± EBRT) for localized pancreatic cancer in the past three decades and to analyze prognostic factors by multivariate analysis. Methods and Materials Records for 322 patients with pancreatic cancer treated by IORT ± EBRT in Tohoku University Hospital between 1980 and 2009 were reviewed. One hundred ninety-two patients who had no distant organ metastases or dissemination at the time of laparotomy were enrolled in the present study. Results Eighty-three patients underwent gross total resection (R0: 48 patients, R1: 35 patients), and 109 patients underwent only biopsy or palliative resection. Fifty-five patients underwent adjuvant EBRT, and 124 underwent adjuvant chemotherapy. The median doses of IORT and EBRT were 25 and 40 Gy, respectively. The median follow-up period was 37.5 months. At the time of the analysis, 166 patients had disease recurrence, and 35 patients had local failure. The 2-year local control (LC) and overall survival (OS) rates were 71.0% and 16.9%, respectively. Comparison of the results for each decade showed that OS was significantly improved decade by decade (2-year: 25.0% vs. 18.8% vs. 4.2%, p < 0.001). Multivariate analysis showed that degree of resection (R0–1 vs. R2, hazard ratio = 1.97, p = 0.001) and adjuvant chemotherapy (yes vs. no, hazard ratio = 1.54, p = 0.028) had significant impacts on OS. Late gastrointestinal morbidity of Common Terminology Criteria for Adverse Events version 3.0 grade 4 or 5 was observed in four patients. Conclusion Excellent local control for pancreatic cancer with few cases of severe late toxicity was achieved by using IORT. OS of patients with pancreatic cancer treated by IORT ± EBRT improved significantly decade by decade. Multivariate analysis showed that degree of resection and adjuvant chemotherapy had significant impacts on OS. |
doi_str_mv | 10.1016/j.ijrobp.2012.01.024 |
format | Article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22058951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301612000685</els_id><sourcerecordid>1439224308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-e47717c234747b03525a235bb9aedd8f49c73e600551d0f50f4c7378c4c8e12b3</originalsourceid><addsrcrecordid>eNqFUk1v1DAQjRCILoV_gJAlLlwSxl-bLAekalVgUSUQBQlOluNMqEPWDrZTsf8eRykcuHCy_fzezOi9KYqnFCoKdPtyqOwQfDtVDCirgFbAxL1iQ5t6V3Ipv94vNsC3UPJMPisexTgAAKW1eFicMSaEBGCboj-4FLSfMOhkb5F80p316SY_pxPpfSAftTMB86ch-3zF8IpwKL-hDuTyV5ZZzCCxjmhybd33EcnBxWTTnKx3C_5eT9o9Lh70eoz45O48L768ufy8f1defXh72F9clUYKkUoUdU1rw7ioRd0Cl0xqxmXb7jR2XdOLnak5bgGkpB30EnqRgboxwjRIWcvPi-drXZ9nUNHYhObGeOfQJMUYyGYnaWa9WFlT8D9njEkdbTQ4jtqhn6Oigu-yRRyaTBUr1QQfY8BeTcEedTgpCmrJQQ1qzUEtOSigKueQZc_uOsztEbu_oj_GZ8LrlYDZjVuLYRl2sbKzYZm18_Z_Hf4tYEbrrNHjDzxhHPwcXHZaURWzRl0vu7CsAmV5DbaN5L8BRO-uYQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1439224308</pqid></control><display><type>article</type><title>Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jingu, Keiichi, M.D ; Tanabe, Takaya, M.D ; Nemoto, Kenji, M.D ; Ariga, Hisanori, M.D ; Umezawa, Rei, M.D ; Ogawa, Yoshihiro, M.D ; Takeda, Ken, M.D ; Koto, Masashi, M.D ; Sugawara, Toshiyuki, M.D ; Kubozono, Masaki, M.D ; Shimizu, Eiji, M.D ; Abe, Keiko, M.D ; Yamada, Shogo, M.D</creator><creatorcontrib>Jingu, Keiichi, M.D ; Tanabe, Takaya, M.D ; Nemoto, Kenji, M.D ; Ariga, Hisanori, M.D ; Umezawa, Rei, M.D ; Ogawa, Yoshihiro, M.D ; Takeda, Ken, M.D ; Koto, Masashi, M.D ; Sugawara, Toshiyuki, M.D ; Kubozono, Masaki, M.D ; Shimizu, Eiji, M.D ; Abe, Keiko, M.D ; Yamada, Shogo, M.D</creatorcontrib><description>Purpose To analyze retrospectively the results of intraoperative radiotherapy (IORT) with or without external beam radiotherapy (± EBRT) for localized pancreatic cancer in the past three decades and to analyze prognostic factors by multivariate analysis. Methods and Materials Records for 322 patients with pancreatic cancer treated by IORT ± EBRT in Tohoku University Hospital between 1980 and 2009 were reviewed. One hundred ninety-two patients who had no distant organ metastases or dissemination at the time of laparotomy were enrolled in the present study. Results Eighty-three patients underwent gross total resection (R0: 48 patients, R1: 35 patients), and 109 patients underwent only biopsy or palliative resection. Fifty-five patients underwent adjuvant EBRT, and 124 underwent adjuvant chemotherapy. The median doses of IORT and EBRT were 25 and 40 Gy, respectively. The median follow-up period was 37.5 months. At the time of the analysis, 166 patients had disease recurrence, and 35 patients had local failure. The 2-year local control (LC) and overall survival (OS) rates were 71.0% and 16.9%, respectively. Comparison of the results for each decade showed that OS was significantly improved decade by decade (2-year: 25.0% vs. 18.8% vs. 4.2%, p < 0.001). Multivariate analysis showed that degree of resection (R0–1 vs. R2, hazard ratio = 1.97, p = 0.001) and adjuvant chemotherapy (yes vs. no, hazard ratio = 1.54, p = 0.028) had significant impacts on OS. Late gastrointestinal morbidity of Common Terminology Criteria for Adverse Events version 3.0 grade 4 or 5 was observed in four patients. Conclusion Excellent local control for pancreatic cancer with few cases of severe late toxicity was achieved by using IORT. OS of patients with pancreatic cancer treated by IORT ± EBRT improved significantly decade by decade. Multivariate analysis showed that degree of resection and adjuvant chemotherapy had significant impacts on OS.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2012.01.024</identifier><identifier>PMID: 22445002</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>30-year experience ; Aged ; BIOPSY ; Chemoradiotherapy ; CHEMOTHERAPY ; COMBINED THERAPY ; DISEASE INCIDENCE ; DOSES ; FAILURES ; Female ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Humans ; Intraoperative Care - methods ; Intraoperative Care - mortality ; Intraoperative radiotherapy ; Japan ; Male ; METASTASES ; Middle Aged ; MULTIVARIATE ANALYSIS ; NEOPLASMS ; PANCREAS ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - radiotherapy ; Pancreatic Neoplasms - surgery ; PATIENTS ; Prognostic factor ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy, Adjuvant - methods ; Retrospective Studies ; Survival Rate ; Time Factors ; TOXICITY</subject><ispartof>International journal of radiation oncology, biology, physics, 2012-07, Vol.83 (4), p.e507-e511</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-e47717c234747b03525a235bb9aedd8f49c73e600551d0f50f4c7378c4c8e12b3</citedby><cites>FETCH-LOGICAL-c544t-e47717c234747b03525a235bb9aedd8f49c73e600551d0f50f4c7378c4c8e12b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301612000685$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22445002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22058951$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Jingu, Keiichi, M.D</creatorcontrib><creatorcontrib>Tanabe, Takaya, M.D</creatorcontrib><creatorcontrib>Nemoto, Kenji, M.D</creatorcontrib><creatorcontrib>Ariga, Hisanori, M.D</creatorcontrib><creatorcontrib>Umezawa, Rei, M.D</creatorcontrib><creatorcontrib>Ogawa, Yoshihiro, M.D</creatorcontrib><creatorcontrib>Takeda, Ken, M.D</creatorcontrib><creatorcontrib>Koto, Masashi, M.D</creatorcontrib><creatorcontrib>Sugawara, Toshiyuki, M.D</creatorcontrib><creatorcontrib>Kubozono, Masaki, M.D</creatorcontrib><creatorcontrib>Shimizu, Eiji, M.D</creatorcontrib><creatorcontrib>Abe, Keiko, M.D</creatorcontrib><creatorcontrib>Yamada, Shogo, M.D</creatorcontrib><title>Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To analyze retrospectively the results of intraoperative radiotherapy (IORT) with or without external beam radiotherapy (± EBRT) for localized pancreatic cancer in the past three decades and to analyze prognostic factors by multivariate analysis. Methods and Materials Records for 322 patients with pancreatic cancer treated by IORT ± EBRT in Tohoku University Hospital between 1980 and 2009 were reviewed. One hundred ninety-two patients who had no distant organ metastases or dissemination at the time of laparotomy were enrolled in the present study. Results Eighty-three patients underwent gross total resection (R0: 48 patients, R1: 35 patients), and 109 patients underwent only biopsy or palliative resection. Fifty-five patients underwent adjuvant EBRT, and 124 underwent adjuvant chemotherapy. The median doses of IORT and EBRT were 25 and 40 Gy, respectively. The median follow-up period was 37.5 months. At the time of the analysis, 166 patients had disease recurrence, and 35 patients had local failure. The 2-year local control (LC) and overall survival (OS) rates were 71.0% and 16.9%, respectively. Comparison of the results for each decade showed that OS was significantly improved decade by decade (2-year: 25.0% vs. 18.8% vs. 4.2%, p < 0.001). Multivariate analysis showed that degree of resection (R0–1 vs. R2, hazard ratio = 1.97, p = 0.001) and adjuvant chemotherapy (yes vs. no, hazard ratio = 1.54, p = 0.028) had significant impacts on OS. Late gastrointestinal morbidity of Common Terminology Criteria for Adverse Events version 3.0 grade 4 or 5 was observed in four patients. Conclusion Excellent local control for pancreatic cancer with few cases of severe late toxicity was achieved by using IORT. OS of patients with pancreatic cancer treated by IORT ± EBRT improved significantly decade by decade. Multivariate analysis showed that degree of resection and adjuvant chemotherapy had significant impacts on OS.</description><subject>30-year experience</subject><subject>Aged</subject><subject>BIOPSY</subject><subject>Chemoradiotherapy</subject><subject>CHEMOTHERAPY</subject><subject>COMBINED THERAPY</subject><subject>DISEASE INCIDENCE</subject><subject>DOSES</subject><subject>FAILURES</subject><subject>Female</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Intraoperative Care - methods</subject><subject>Intraoperative Care - mortality</subject><subject>Intraoperative radiotherapy</subject><subject>Japan</subject><subject>Male</subject><subject>METASTASES</subject><subject>Middle Aged</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>NEOPLASMS</subject><subject>PANCREAS</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - radiotherapy</subject><subject>Pancreatic Neoplasms - surgery</subject><subject>PATIENTS</subject><subject>Prognostic factor</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>TOXICITY</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk1v1DAQjRCILoV_gJAlLlwSxl-bLAekalVgUSUQBQlOluNMqEPWDrZTsf8eRykcuHCy_fzezOi9KYqnFCoKdPtyqOwQfDtVDCirgFbAxL1iQ5t6V3Ipv94vNsC3UPJMPisexTgAAKW1eFicMSaEBGCboj-4FLSfMOhkb5F80p316SY_pxPpfSAftTMB86ch-3zF8IpwKL-hDuTyV5ZZzCCxjmhybd33EcnBxWTTnKx3C_5eT9o9Lh70eoz45O48L768ufy8f1defXh72F9clUYKkUoUdU1rw7ioRd0Cl0xqxmXb7jR2XdOLnak5bgGkpB30EnqRgboxwjRIWcvPi-drXZ9nUNHYhObGeOfQJMUYyGYnaWa9WFlT8D9njEkdbTQ4jtqhn6Oigu-yRRyaTBUr1QQfY8BeTcEedTgpCmrJQQ1qzUEtOSigKueQZc_uOsztEbu_oj_GZ8LrlYDZjVuLYRl2sbKzYZm18_Z_Hf4tYEbrrNHjDzxhHPwcXHZaURWzRl0vu7CsAmV5DbaN5L8BRO-uYQ</recordid><startdate>20120715</startdate><enddate>20120715</enddate><creator>Jingu, Keiichi, M.D</creator><creator>Tanabe, Takaya, M.D</creator><creator>Nemoto, Kenji, M.D</creator><creator>Ariga, Hisanori, M.D</creator><creator>Umezawa, Rei, M.D</creator><creator>Ogawa, Yoshihiro, M.D</creator><creator>Takeda, Ken, M.D</creator><creator>Koto, Masashi, M.D</creator><creator>Sugawara, Toshiyuki, M.D</creator><creator>Kubozono, Masaki, M.D</creator><creator>Shimizu, Eiji, M.D</creator><creator>Abe, Keiko, M.D</creator><creator>Yamada, Shogo, M.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20120715</creationdate><title>Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan</title><author>Jingu, Keiichi, M.D ; Tanabe, Takaya, M.D ; Nemoto, Kenji, M.D ; Ariga, Hisanori, M.D ; Umezawa, Rei, M.D ; Ogawa, Yoshihiro, M.D ; Takeda, Ken, M.D ; Koto, Masashi, M.D ; Sugawara, Toshiyuki, M.D ; Kubozono, Masaki, M.D ; Shimizu, Eiji, M.D ; Abe, Keiko, M.D ; Yamada, Shogo, M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-e47717c234747b03525a235bb9aedd8f49c73e600551d0f50f4c7378c4c8e12b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>30-year experience</topic><topic>Aged</topic><topic>BIOPSY</topic><topic>Chemoradiotherapy</topic><topic>CHEMOTHERAPY</topic><topic>COMBINED THERAPY</topic><topic>DISEASE INCIDENCE</topic><topic>DOSES</topic><topic>FAILURES</topic><topic>Female</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Intraoperative Care - methods</topic><topic>Intraoperative Care - mortality</topic><topic>Intraoperative radiotherapy</topic><topic>Japan</topic><topic>Male</topic><topic>METASTASES</topic><topic>Middle Aged</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>NEOPLASMS</topic><topic>PANCREAS</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - radiotherapy</topic><topic>Pancreatic Neoplasms - surgery</topic><topic>PATIENTS</topic><topic>Prognostic factor</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>TOXICITY</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jingu, Keiichi, M.D</creatorcontrib><creatorcontrib>Tanabe, Takaya, M.D</creatorcontrib><creatorcontrib>Nemoto, Kenji, M.D</creatorcontrib><creatorcontrib>Ariga, Hisanori, M.D</creatorcontrib><creatorcontrib>Umezawa, Rei, M.D</creatorcontrib><creatorcontrib>Ogawa, Yoshihiro, M.D</creatorcontrib><creatorcontrib>Takeda, Ken, M.D</creatorcontrib><creatorcontrib>Koto, Masashi, M.D</creatorcontrib><creatorcontrib>Sugawara, Toshiyuki, M.D</creatorcontrib><creatorcontrib>Kubozono, Masaki, M.D</creatorcontrib><creatorcontrib>Shimizu, Eiji, M.D</creatorcontrib><creatorcontrib>Abe, Keiko, M.D</creatorcontrib><creatorcontrib>Yamada, Shogo, M.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jingu, Keiichi, M.D</au><au>Tanabe, Takaya, M.D</au><au>Nemoto, Kenji, M.D</au><au>Ariga, Hisanori, M.D</au><au>Umezawa, Rei, M.D</au><au>Ogawa, Yoshihiro, M.D</au><au>Takeda, Ken, M.D</au><au>Koto, Masashi, M.D</au><au>Sugawara, Toshiyuki, M.D</au><au>Kubozono, Masaki, M.D</au><au>Shimizu, Eiji, M.D</au><au>Abe, Keiko, M.D</au><au>Yamada, Shogo, M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2012-07-15</date><risdate>2012</risdate><volume>83</volume><issue>4</issue><spage>e507</spage><epage>e511</epage><pages>e507-e511</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose To analyze retrospectively the results of intraoperative radiotherapy (IORT) with or without external beam radiotherapy (± EBRT) for localized pancreatic cancer in the past three decades and to analyze prognostic factors by multivariate analysis. Methods and Materials Records for 322 patients with pancreatic cancer treated by IORT ± EBRT in Tohoku University Hospital between 1980 and 2009 were reviewed. One hundred ninety-two patients who had no distant organ metastases or dissemination at the time of laparotomy were enrolled in the present study. Results Eighty-three patients underwent gross total resection (R0: 48 patients, R1: 35 patients), and 109 patients underwent only biopsy or palliative resection. Fifty-five patients underwent adjuvant EBRT, and 124 underwent adjuvant chemotherapy. The median doses of IORT and EBRT were 25 and 40 Gy, respectively. The median follow-up period was 37.5 months. At the time of the analysis, 166 patients had disease recurrence, and 35 patients had local failure. The 2-year local control (LC) and overall survival (OS) rates were 71.0% and 16.9%, respectively. Comparison of the results for each decade showed that OS was significantly improved decade by decade (2-year: 25.0% vs. 18.8% vs. 4.2%, p < 0.001). Multivariate analysis showed that degree of resection (R0–1 vs. R2, hazard ratio = 1.97, p = 0.001) and adjuvant chemotherapy (yes vs. no, hazard ratio = 1.54, p = 0.028) had significant impacts on OS. Late gastrointestinal morbidity of Common Terminology Criteria for Adverse Events version 3.0 grade 4 or 5 was observed in four patients. Conclusion Excellent local control for pancreatic cancer with few cases of severe late toxicity was achieved by using IORT. OS of patients with pancreatic cancer treated by IORT ± EBRT improved significantly decade by decade. Multivariate analysis showed that degree of resection and adjuvant chemotherapy had significant impacts on OS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22445002</pmid><doi>10.1016/j.ijrobp.2012.01.024</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0360-3016 |
ispartof | International journal of radiation oncology, biology, physics, 2012-07, Vol.83 (4), p.e507-e511 |
issn | 0360-3016 1879-355X |
language | eng |
recordid | cdi_osti_scitechconnect_22058951 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | 30-year experience Aged BIOPSY Chemoradiotherapy CHEMOTHERAPY COMBINED THERAPY DISEASE INCIDENCE DOSES FAILURES Female HAZARDS Hematology, Oncology and Palliative Medicine Humans Intraoperative Care - methods Intraoperative Care - mortality Intraoperative radiotherapy Japan Male METASTASES Middle Aged MULTIVARIATE ANALYSIS NEOPLASMS PANCREAS Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - radiotherapy Pancreatic Neoplasms - surgery PATIENTS Prognostic factor Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy, Adjuvant - methods Retrospective Studies Survival Rate Time Factors TOXICITY |
title | Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T07%3A15%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraoperative%20Radiotherapy%20for%20Pancreatic%20Cancer:%2030-Year%20Experience%20in%20a%20Single%20Institution%20in%20Japan&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Jingu,%20Keiichi,%20M.D&rft.date=2012-07-15&rft.volume=83&rft.issue=4&rft.spage=e507&rft.epage=e511&rft.pages=e507-e511&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2012.01.024&rft_dat=%3Cproquest_osti_%3E1439224308%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1439224308&rft_id=info:pmid/22445002&rft_els_id=1_s2_0_S0360301612000685&rfr_iscdi=true |